XenoPort, Inc. And DBV Technologies SA: Two Healthcare Stocks With Opposing Momentum

The $1.73 billion clinical-stage biopharmaceutical company, DBV Technologies SA – ADR (NASDAQ:DBVT) is focused on developing and commercializing treatments for severe allergies. Its core platform, Viaskin is an electrostatic patch offering non-invasive immunotherapy to patients. The company has three products in its pipeline, which are currently in the Phase III developmental stage; namely Viaskin Peanut, Viaskin Milk, and Viaskin Egg. Since its IPO in October of last year, DBV Technologies’ stock has appreciated by more than 75%. Morgan Stanley’s upgrade gives further validation to investors that the company’s business model and progress are on track to materializing into something substantial in the future.

Hedge funds were fairly bullish towards DBV Technologies SA – ADR (NASDAQ:DBVT) during the second quarter. Among the funds that we track, a total of 12 firms had an aggregate investment of $149 million in the company at the end of June compared to nine hedge funds with $106.49 million in shares at the end of March. The smart money we track held 13.1% of the company’s shares. Baker Bros. Advisors is the largest stockholder of DBV Technologies within our database, holding 2.56 million shares valued at $76.37 million. It is followed by Israel Englander‘s Millennium Management and Jacob Gottlieb’s Visium Asset Management, with respective holdings of 592,200 shares valued at $17.64 million and 444,400 shares valued at $13.23 million.

Disclosure: None